SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Phage Therapeutics International Inc – ‘10SB12G/A’ on 12/5/01 – EX-10.8

On:  Wednesday, 12/5/01   ·   Accession #:  912057-1-542027   ·   File #:  0-31961

Previous ‘10SB12G’:  ‘10SB12G/A’ on 6/6/01   ·   Latest ‘10SB12G’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

12/05/01  Phage Therapeutics Int’l Inc      10SB12G/A             24:1.4M                                   Merrill Corp/FA

Amendment to Registration of Securities of a Small-Business Issuer   —   Form 10-SB
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10SB12G/A   Amendment to Registration of Securities of a        HTML    725K 
                          Small-Business Issuer                                  
 2: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     19K 
 3: EX-10.1     Material Contract                                   HTML     34K 
11: EX-10.10    Material Contract                                   HTML     79K 
12: EX-10.11    Material Contract                                   HTML     78K 
13: EX-10.12    Material Contract                                   HTML     53K 
14: EX-10.13    Material Contract                                   HTML     79K 
15: EX-10.14    Material Contract                                   HTML     22K 
16: EX-10.15    Material Contract                                   HTML     25K 
 4: EX-10.2     Material Contract                                   HTML     30K 
17: EX-10.22    Material Contract                                   HTML     38K 
18: EX-10.23    Material Contract                                   HTML     43K 
19: EX-10.24    Material Contract                                   HTML     43K 
20: EX-10.28    Material Contract                                   HTML     44K 
21: EX-10.29    Material Contract                                   HTML     64K 
 5: EX-10.3     Material Contract                                   HTML     42K 
22: EX-10.30    Material Contract                                   HTML     18K 
23: EX-10.33    Material Contract                                   HTML     46K 
 6: EX-10.4     Material Contract                                   HTML     80K 
 7: EX-10.5     Material Contract                                   HTML     22K 
 8: EX-10.6     Material Contract                                   HTML     18K 
 9: EX-10.8     Material Contract                                   HTML     19K 
10: EX-10.9     Material Contract                                   HTML     23K 
24: EX-21       Subsidiaries of the Registrant                      HTML      9K 


EX-10.8   —   Material Contract
Exhibit Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
"Stock Purchase Amending Agreement
"QuickLinks

This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Prepared by MERRILL CORPORATION  

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 10.8


STOCK PURCHASE AMENDING AGREEMENT

    THIS AGREEMENT dated as of the 22nd day of November, 2000.

BETWEEN:

    PHAGE THERAPEUTICS INTERNATIONAL, INC., a company incorporated under the laws of Florida, having an office and address at 19017 120th Avenue NE, Suite 102, Bothel, Washington 98011.

    (the "Company")

AND:

    ROBERT MILLER, a businessman having an address at 1645 South Miami Avenue, Miami, Florida 33129;

    BOLIVAR LONGINES SA, a company having a registered office at Centro Comerical Naraya, Piso 4 Oficina L-10, Alta Vista, Puerto Ordaz, Venezuela;

    RICARDO REQUENA, a businessman having an address at 25 de Mayo 444 Piso 2, 11000 Montevideo, Urguay;

    CADAQUES SA., a company having an address at Benito Blanco 675, Apt. 401, 11300 Montevideo, Urguay;

    BLANCO DE LONGO, a businesswoman having an address at Carace 524, Apt. 701, Montevideo, Urguay;

    STRATTON SA, a company having a registered office at 25 de Mayo 444 Piso 2, 11000 Montevideo, Urguay;

    GIG LIMITED, a company having a registered office at 105 Marbel Drive, Grand Cayman, BWI.

    (collectively the "Purchasers")

WHEREAS:

A.
On October 23, 2000, the Company and Purchasers entered into a purchase and sale agreement ("Purchase Agreement") whereby the Company has agreed to sell to the Purchasers 2,142,857 units for an aggregate purchaser price of $1,500,000. Each "Unit" will consist of one share of the Company's common stock with a par value of $0.001 per share (the "Common Stock") and one Common Stock purchase warrant (the "Warrant"). Every one and a half Warrants will entitle the holder to acquire one additional share of Common Stock of Phage at an exercise price of $0.70 per share;

B.
The Purchasers have agreed to invest an additional $1,500,000 into the Company within seven (7) days from the date of filing of the Company's Form 10SB-12g with the Securities and Exchange Commission. In consideration of this investment, the Company has agreed to issue an additional 2,142,857 Units to the Purchasers.

C.
The parties have agreed to amend the Purchase Agreement as herein provided.

1


    NOW THEREFORE, for valuable consideration and upon the mutual covenants and promises contained herein, the parties hereto agree as follows:

Recitals, Clause C, Additional Purchase Price and Terms of Payment

1.
Clause C, in the Recitals shall be amended to state "The Purchasers have agreed to invest an additional One Million Five Hundred Thousand Dollars ($1,500,000) in equity into Phage by January 15, 2001. In consideration of this investment Phage has agreed to issue to the Purchasers an additional 2,142,857 Units."

Article 1:
Definitions, Second Closing Date

2.
Article 1, Definitions, "Second Closing Date" be amended to state "Second Closing Date" means January 15, 2001."

General

3.
All other terms of the Purchase Agreement will remain the same.

4.
The Purchase Agreement remains in full force and effect except as expressly amended by this Amending Agreement.

2


    IN WITNESS WHEREOF the parties hereto have caused this Agreement to be duly executed, all as of the day and year first above written.

PHAGE THERAPEUTICS INTERNATIONAL, INC.    

/s/ 
DARREN PYLOT   

 

 
By: Darren Pylot, President
   

PURCHASERS:

 

 

/s/ 
ROBERT MILLER   

 

/s/ 
UNREADABLE   
Name: Robert Miller   Name: Bolivar Longines SA

/s/ 
RICARDO REQUENA   

 

/s/ 
UNREADABLE   
Name: Ricardo Requena   Name: Cadaques S.A.

/s/ 
BLANCA DE LONGO   

 

/s/ 
UNREADABLE   
Name: Blanca de Longo   Name: Stratton S.A.

/s/ 
UNREADABLE   

 

 
Name: GIG Limited    

3




QuickLinks

STOCK PURCHASE AMENDING AGREEMENT

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10SB12G/A’ Filing    Date    Other Filings
Filed on:12/5/01
1/15/013
10/23/00
 List all Filings 
Top
Filing Submission 0000912057-01-542027   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 2:16:49.1pm ET